Global Competent Cells research

Competent Cells Comprehensive Study by Type (Cloned Competent Cells, Agrobacterium Tumefaciens Competent Cells, Expression Competent Cells), Application (Cloning {Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-throughput Cloning}, Protein Expression, Other Applications {Mutagenesis, Single-stranded DNA Production, Lentiviral Vector Production, Large Plasmid Transformation}), Phases (Lag Phase, Log Phase, Stationary Phase, Death Phase), Method (Chemical Transformation, Electroporation), End User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs)) Players and Region - Global Market Outlook to 2025

Competent Cells Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 11%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Competent Cells Market Overview:
Competent Cells are E. coli cells possessing altered cell walls that enable the integration of foreign DNA. It is used in molecular cloning workflows, protein expression, and any a variety of applications using plasmid DNA. Competent cells have to be reliable and as efficient as possible and are made competent by a process that uses calcium chloride and heat shock. Cells that are undergoing very rapid growth are made competent more easily than cells in other stages. The ongoing developments in molecular cloning research are driving the demand for competent cells. According to AMA, the Global Competent Cells market is expected to see growth rate of 11.0%

Market Drivers
  • Advancements in Molecular Cloning Research Due to the Emergence of New Technologies
  • Growing Commercial Demand for Molecular Cloned Products and Recombinant Proteins

Market Trend
  • Increasing Research in DNA technologies

Restraints
  • High Cost of Competent Cell Kits

Opportunities
  • Advancements in Molecular Cloning Research
  • Emerging Applications of Competent Cells

Challenges
  • Lack of Skilled Professionals


Competitive Landscape:

Some of the key players profiled in the report are Merck KGaA (Germany), Promega Corporation (United States), Thermo Fisher Scientific, Inc. (United States), New England Biolabs (United States), Takara Bio (Japan), Agilent Technologies (United States), Lucigen (United States), QIAGEN N.V. (Germany), OriGene Technologies (United States), Bioline (United Kingdom), Zymo Research (United States), Beijing TransGen Biotech Co., Ltd. (China), Source BioScience (United Kingdom), IBA GmBH (Germany), Genewiz (United States) and BioDynamics Laboratory, Inc. (Japan). The Players having a strong hold in the market are Merck, Thermo Fisher Scientific, Agilent Technologies, and Promega. Additionally, following companies can also be profiled that are part of our coverage like GCC Biotech (India), SMOBIO Technology (Taiwan), GeneScript Corporation (United States), Bio-Rad Laboratories (United States), Life Technologies (India) Pvt. Ltd. (India), Cell Applications, Inc. (United States), Delphi Genetics (Belgium), Scarab Genomics, LLC (U.S.) and Yeastern Biotech Co., Ltd. (Taiwan). Analyst at AdvanceMarketAnalytics see North America and Europe Players to retain maximum share of Global Competent Cells market by 2025. Considering Market by Phases, the sub-segment i.e. Lag Phase will boost the Competent Cells market. Considering Market by Method, the sub-segment i.e. Chemical Transformation will boost the Competent Cells market. Considering Market by End User, the sub-segment i.e. Pharmaceutical and Biotechnology Companies will boost the Competent Cells market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Competent Cells market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Competent Cells market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Competent Cells Manufacturer, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Cloned Competent Cells
  • Agrobacterium Tumefaciens Competent Cells
  • Expression Competent Cells
By Application
  • Cloning {Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-throughput Cloning}
  • Protein Expression
  • Other Applications {Mutagenesis, Single-stranded DNA Production, Lentiviral Vector Production, Large Plasmid Transformation}
By Phases
  • Lag Phase
  • Log Phase
  • Stationary Phase
  • Death Phase

By Method
  • Chemical Transformation
  • Electroporation

By End User
  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations (CROs)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Advancements in Molecular Cloning Research Due to the Emergence of New Technologies
      • 3.2.2. Growing Commercial Demand for Molecular Cloned Products and Recombinant Proteins
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Increasing Research in DNA technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Competent Cells, by Type, Application, Phases, Method, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Competent Cells (Value)
      • 5.2.1. Global Competent Cells by: Type (Value)
        • 5.2.1.1. Cloned Competent Cells
        • 5.2.1.2. Agrobacterium Tumefaciens Competent Cells
        • 5.2.1.3. Expression Competent Cells
      • 5.2.2. Global Competent Cells by: Application (Value)
        • 5.2.2.1. Cloning {Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-throughput Cloning}
        • 5.2.2.2. Protein Expression
        • 5.2.2.3. Other Applications {Mutagenesis, Single-stranded DNA Production, Lentiviral Vector Production, Large Plasmid Transformation}
      • 5.2.3. Global Competent Cells by: Phases (Value)
        • 5.2.3.1. Lag Phase
        • 5.2.3.2. Log Phase
        • 5.2.3.3. Stationary Phase
        • 5.2.3.4. Death Phase
      • 5.2.4. Global Competent Cells by: Method (Value)
        • 5.2.4.1. Chemical Transformation
        • 5.2.4.2. Electroporation
      • 5.2.5. Global Competent Cells by: End User (Value)
        • 5.2.5.1. Pharmaceutical and Biotechnology Companies
        • 5.2.5.2. Academic Research Institutes
        • 5.2.5.3. Contract Research Organizations (CROs)
      • 5.2.6. Global Competent Cells Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Competent Cells: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Promega Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. New England Biolabs (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Takara Bio (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Agilent Technologies (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lucigen (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. QIAGEN N.V. (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. OriGene Technologies (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bioline (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Zymo Research (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Beijing TransGen Biotech Co., Ltd. (China)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Source BioScience (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. IBA GmBH (Germany)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Genewiz (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. BioDynamics Laboratory, Inc. (Japan)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Competent Cells Sale, by Type, Application, Phases, Method, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Competent Cells (Value)
      • 7.2.1. Global Competent Cells by: Type (Value)
        • 7.2.1.1. Cloned Competent Cells
        • 7.2.1.2. Agrobacterium Tumefaciens Competent Cells
        • 7.2.1.3. Expression Competent Cells
      • 7.2.2. Global Competent Cells by: Application (Value)
        • 7.2.2.1. Cloning {Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-throughput Cloning}
        • 7.2.2.2. Protein Expression
        • 7.2.2.3. Other Applications {Mutagenesis, Single-stranded DNA Production, Lentiviral Vector Production, Large Plasmid Transformation}
      • 7.2.3. Global Competent Cells by: Phases (Value)
        • 7.2.3.1. Lag Phase
        • 7.2.3.2. Log Phase
        • 7.2.3.3. Stationary Phase
        • 7.2.3.4. Death Phase
      • 7.2.4. Global Competent Cells by: Method (Value)
        • 7.2.4.1. Chemical Transformation
        • 7.2.4.2. Electroporation
      • 7.2.5. Global Competent Cells by: End User (Value)
        • 7.2.5.1. Pharmaceutical and Biotechnology Companies
        • 7.2.5.2. Academic Research Institutes
        • 7.2.5.3. Contract Research Organizations (CROs)
      • 7.2.6. Global Competent Cells Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Competent Cells: by Type(USD Billion)
  • Table 2. Competent Cells Cloned Competent Cells , by Region USD Billion (2014-2019)
  • Table 3. Competent Cells Agrobacterium Tumefaciens Competent Cells , by Region USD Billion (2014-2019)
  • Table 4. Competent Cells Expression Competent Cells , by Region USD Billion (2014-2019)
  • Table 5. Competent Cells: by Application(USD Billion)
  • Table 6. Competent Cells Cloning {Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-throughput Cloning} , by Region USD Billion (2014-2019)
  • Table 7. Competent Cells Protein Expression , by Region USD Billion (2014-2019)
  • Table 8. Competent Cells Other Applications {Mutagenesis, Single-stranded DNA Production, Lentiviral Vector Production, Large Plasmid Transformation} , by Region USD Billion (2014-2019)
  • Table 9. Competent Cells: by Phases(USD Billion)
  • Table 10. Competent Cells Lag Phase , by Region USD Billion (2014-2019)
  • Table 11. Competent Cells Log Phase , by Region USD Billion (2014-2019)
  • Table 12. Competent Cells Stationary Phase , by Region USD Billion (2014-2019)
  • Table 13. Competent Cells Death Phase , by Region USD Billion (2014-2019)
  • Table 14. Competent Cells: by Method(USD Billion)
  • Table 15. Competent Cells Chemical Transformation , by Region USD Billion (2014-2019)
  • Table 16. Competent Cells Electroporation , by Region USD Billion (2014-2019)
  • Table 17. Competent Cells: by End User(USD Billion)
  • Table 18. Competent Cells Pharmaceutical and Biotechnology Companies , by Region USD Billion (2014-2019)
  • Table 19. Competent Cells Academic Research Institutes , by Region USD Billion (2014-2019)
  • Table 20. Competent Cells Contract Research Organizations (CROs) , by Region USD Billion (2014-2019)
  • Table 21. South America Competent Cells, by Country USD Billion (2014-2019)
  • Table 22. South America Competent Cells, by Type USD Billion (2014-2019)
  • Table 23. South America Competent Cells, by Application USD Billion (2014-2019)
  • Table 24. South America Competent Cells, by Phases USD Billion (2014-2019)
  • Table 25. South America Competent Cells, by Method USD Billion (2014-2019)
  • Table 26. South America Competent Cells, by End User USD Billion (2014-2019)
  • Table 27. Brazil Competent Cells, by Type USD Billion (2014-2019)
  • Table 28. Brazil Competent Cells, by Application USD Billion (2014-2019)
  • Table 29. Brazil Competent Cells, by Phases USD Billion (2014-2019)
  • Table 30. Brazil Competent Cells, by Method USD Billion (2014-2019)
  • Table 31. Brazil Competent Cells, by End User USD Billion (2014-2019)
  • Table 32. Argentina Competent Cells, by Type USD Billion (2014-2019)
  • Table 33. Argentina Competent Cells, by Application USD Billion (2014-2019)
  • Table 34. Argentina Competent Cells, by Phases USD Billion (2014-2019)
  • Table 35. Argentina Competent Cells, by Method USD Billion (2014-2019)
  • Table 36. Argentina Competent Cells, by End User USD Billion (2014-2019)
  • Table 37. Rest of South America Competent Cells, by Type USD Billion (2014-2019)
  • Table 38. Rest of South America Competent Cells, by Application USD Billion (2014-2019)
  • Table 39. Rest of South America Competent Cells, by Phases USD Billion (2014-2019)
  • Table 40. Rest of South America Competent Cells, by Method USD Billion (2014-2019)
  • Table 41. Rest of South America Competent Cells, by End User USD Billion (2014-2019)
  • Table 42. Asia Pacific Competent Cells, by Country USD Billion (2014-2019)
  • Table 43. Asia Pacific Competent Cells, by Type USD Billion (2014-2019)
  • Table 44. Asia Pacific Competent Cells, by Application USD Billion (2014-2019)
  • Table 45. Asia Pacific Competent Cells, by Phases USD Billion (2014-2019)
  • Table 46. Asia Pacific Competent Cells, by Method USD Billion (2014-2019)
  • Table 47. Asia Pacific Competent Cells, by End User USD Billion (2014-2019)
  • Table 48. China Competent Cells, by Type USD Billion (2014-2019)
  • Table 49. China Competent Cells, by Application USD Billion (2014-2019)
  • Table 50. China Competent Cells, by Phases USD Billion (2014-2019)
  • Table 51. China Competent Cells, by Method USD Billion (2014-2019)
  • Table 52. China Competent Cells, by End User USD Billion (2014-2019)
  • Table 53. Japan Competent Cells, by Type USD Billion (2014-2019)
  • Table 54. Japan Competent Cells, by Application USD Billion (2014-2019)
  • Table 55. Japan Competent Cells, by Phases USD Billion (2014-2019)
  • Table 56. Japan Competent Cells, by Method USD Billion (2014-2019)
  • Table 57. Japan Competent Cells, by End User USD Billion (2014-2019)
  • Table 58. India Competent Cells, by Type USD Billion (2014-2019)
  • Table 59. India Competent Cells, by Application USD Billion (2014-2019)
  • Table 60. India Competent Cells, by Phases USD Billion (2014-2019)
  • Table 61. India Competent Cells, by Method USD Billion (2014-2019)
  • Table 62. India Competent Cells, by End User USD Billion (2014-2019)
  • Table 63. South Korea Competent Cells, by Type USD Billion (2014-2019)
  • Table 64. South Korea Competent Cells, by Application USD Billion (2014-2019)
  • Table 65. South Korea Competent Cells, by Phases USD Billion (2014-2019)
  • Table 66. South Korea Competent Cells, by Method USD Billion (2014-2019)
  • Table 67. South Korea Competent Cells, by End User USD Billion (2014-2019)
  • Table 68. Taiwan Competent Cells, by Type USD Billion (2014-2019)
  • Table 69. Taiwan Competent Cells, by Application USD Billion (2014-2019)
  • Table 70. Taiwan Competent Cells, by Phases USD Billion (2014-2019)
  • Table 71. Taiwan Competent Cells, by Method USD Billion (2014-2019)
  • Table 72. Taiwan Competent Cells, by End User USD Billion (2014-2019)
  • Table 73. Australia Competent Cells, by Type USD Billion (2014-2019)
  • Table 74. Australia Competent Cells, by Application USD Billion (2014-2019)
  • Table 75. Australia Competent Cells, by Phases USD Billion (2014-2019)
  • Table 76. Australia Competent Cells, by Method USD Billion (2014-2019)
  • Table 77. Australia Competent Cells, by End User USD Billion (2014-2019)
  • Table 78. Rest of Asia-Pacific Competent Cells, by Type USD Billion (2014-2019)
  • Table 79. Rest of Asia-Pacific Competent Cells, by Application USD Billion (2014-2019)
  • Table 80. Rest of Asia-Pacific Competent Cells, by Phases USD Billion (2014-2019)
  • Table 81. Rest of Asia-Pacific Competent Cells, by Method USD Billion (2014-2019)
  • Table 82. Rest of Asia-Pacific Competent Cells, by End User USD Billion (2014-2019)
  • Table 83. Europe Competent Cells, by Country USD Billion (2014-2019)
  • Table 84. Europe Competent Cells, by Type USD Billion (2014-2019)
  • Table 85. Europe Competent Cells, by Application USD Billion (2014-2019)
  • Table 86. Europe Competent Cells, by Phases USD Billion (2014-2019)
  • Table 87. Europe Competent Cells, by Method USD Billion (2014-2019)
  • Table 88. Europe Competent Cells, by End User USD Billion (2014-2019)
  • Table 89. Germany Competent Cells, by Type USD Billion (2014-2019)
  • Table 90. Germany Competent Cells, by Application USD Billion (2014-2019)
  • Table 91. Germany Competent Cells, by Phases USD Billion (2014-2019)
  • Table 92. Germany Competent Cells, by Method USD Billion (2014-2019)
  • Table 93. Germany Competent Cells, by End User USD Billion (2014-2019)
  • Table 94. France Competent Cells, by Type USD Billion (2014-2019)
  • Table 95. France Competent Cells, by Application USD Billion (2014-2019)
  • Table 96. France Competent Cells, by Phases USD Billion (2014-2019)
  • Table 97. France Competent Cells, by Method USD Billion (2014-2019)
  • Table 98. France Competent Cells, by End User USD Billion (2014-2019)
  • Table 99. Italy Competent Cells, by Type USD Billion (2014-2019)
  • Table 100. Italy Competent Cells, by Application USD Billion (2014-2019)
  • Table 101. Italy Competent Cells, by Phases USD Billion (2014-2019)
  • Table 102. Italy Competent Cells, by Method USD Billion (2014-2019)
  • Table 103. Italy Competent Cells, by End User USD Billion (2014-2019)
  • Table 104. United Kingdom Competent Cells, by Type USD Billion (2014-2019)
  • Table 105. United Kingdom Competent Cells, by Application USD Billion (2014-2019)
  • Table 106. United Kingdom Competent Cells, by Phases USD Billion (2014-2019)
  • Table 107. United Kingdom Competent Cells, by Method USD Billion (2014-2019)
  • Table 108. United Kingdom Competent Cells, by End User USD Billion (2014-2019)
  • Table 109. Netherlands Competent Cells, by Type USD Billion (2014-2019)
  • Table 110. Netherlands Competent Cells, by Application USD Billion (2014-2019)
  • Table 111. Netherlands Competent Cells, by Phases USD Billion (2014-2019)
  • Table 112. Netherlands Competent Cells, by Method USD Billion (2014-2019)
  • Table 113. Netherlands Competent Cells, by End User USD Billion (2014-2019)
  • Table 114. Rest of Europe Competent Cells, by Type USD Billion (2014-2019)
  • Table 115. Rest of Europe Competent Cells, by Application USD Billion (2014-2019)
  • Table 116. Rest of Europe Competent Cells, by Phases USD Billion (2014-2019)
  • Table 117. Rest of Europe Competent Cells, by Method USD Billion (2014-2019)
  • Table 118. Rest of Europe Competent Cells, by End User USD Billion (2014-2019)
  • Table 119. MEA Competent Cells, by Country USD Billion (2014-2019)
  • Table 120. MEA Competent Cells, by Type USD Billion (2014-2019)
  • Table 121. MEA Competent Cells, by Application USD Billion (2014-2019)
  • Table 122. MEA Competent Cells, by Phases USD Billion (2014-2019)
  • Table 123. MEA Competent Cells, by Method USD Billion (2014-2019)
  • Table 124. MEA Competent Cells, by End User USD Billion (2014-2019)
  • Table 125. Middle East Competent Cells, by Type USD Billion (2014-2019)
  • Table 126. Middle East Competent Cells, by Application USD Billion (2014-2019)
  • Table 127. Middle East Competent Cells, by Phases USD Billion (2014-2019)
  • Table 128. Middle East Competent Cells, by Method USD Billion (2014-2019)
  • Table 129. Middle East Competent Cells, by End User USD Billion (2014-2019)
  • Table 130. Africa Competent Cells, by Type USD Billion (2014-2019)
  • Table 131. Africa Competent Cells, by Application USD Billion (2014-2019)
  • Table 132. Africa Competent Cells, by Phases USD Billion (2014-2019)
  • Table 133. Africa Competent Cells, by Method USD Billion (2014-2019)
  • Table 134. Africa Competent Cells, by End User USD Billion (2014-2019)
  • Table 135. North America Competent Cells, by Country USD Billion (2014-2019)
  • Table 136. North America Competent Cells, by Type USD Billion (2014-2019)
  • Table 137. North America Competent Cells, by Application USD Billion (2014-2019)
  • Table 138. North America Competent Cells, by Phases USD Billion (2014-2019)
  • Table 139. North America Competent Cells, by Method USD Billion (2014-2019)
  • Table 140. North America Competent Cells, by End User USD Billion (2014-2019)
  • Table 141. United States Competent Cells, by Type USD Billion (2014-2019)
  • Table 142. United States Competent Cells, by Application USD Billion (2014-2019)
  • Table 143. United States Competent Cells, by Phases USD Billion (2014-2019)
  • Table 144. United States Competent Cells, by Method USD Billion (2014-2019)
  • Table 145. United States Competent Cells, by End User USD Billion (2014-2019)
  • Table 146. Canada Competent Cells, by Type USD Billion (2014-2019)
  • Table 147. Canada Competent Cells, by Application USD Billion (2014-2019)
  • Table 148. Canada Competent Cells, by Phases USD Billion (2014-2019)
  • Table 149. Canada Competent Cells, by Method USD Billion (2014-2019)
  • Table 150. Canada Competent Cells, by End User USD Billion (2014-2019)
  • Table 151. Mexico Competent Cells, by Type USD Billion (2014-2019)
  • Table 152. Mexico Competent Cells, by Application USD Billion (2014-2019)
  • Table 153. Mexico Competent Cells, by Phases USD Billion (2014-2019)
  • Table 154. Mexico Competent Cells, by Method USD Billion (2014-2019)
  • Table 155. Mexico Competent Cells, by End User USD Billion (2014-2019)
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Competent Cells: by Type(USD Billion)
  • Table 173. Competent Cells Cloned Competent Cells , by Region USD Billion (2020-2025)
  • Table 174. Competent Cells Agrobacterium Tumefaciens Competent Cells , by Region USD Billion (2020-2025)
  • Table 175. Competent Cells Expression Competent Cells , by Region USD Billion (2020-2025)
  • Table 176. Competent Cells: by Application(USD Billion)
  • Table 177. Competent Cells Cloning {Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-throughput Cloning} , by Region USD Billion (2020-2025)
  • Table 178. Competent Cells Protein Expression , by Region USD Billion (2020-2025)
  • Table 179. Competent Cells Other Applications {Mutagenesis, Single-stranded DNA Production, Lentiviral Vector Production, Large Plasmid Transformation} , by Region USD Billion (2020-2025)
  • Table 180. Competent Cells: by Phases(USD Billion)
  • Table 181. Competent Cells Lag Phase , by Region USD Billion (2020-2025)
  • Table 182. Competent Cells Log Phase , by Region USD Billion (2020-2025)
  • Table 183. Competent Cells Stationary Phase , by Region USD Billion (2020-2025)
  • Table 184. Competent Cells Death Phase , by Region USD Billion (2020-2025)
  • Table 185. Competent Cells: by Method(USD Billion)
  • Table 186. Competent Cells Chemical Transformation , by Region USD Billion (2020-2025)
  • Table 187. Competent Cells Electroporation , by Region USD Billion (2020-2025)
  • Table 188. Competent Cells: by End User(USD Billion)
  • Table 189. Competent Cells Pharmaceutical and Biotechnology Companies , by Region USD Billion (2020-2025)
  • Table 190. Competent Cells Academic Research Institutes , by Region USD Billion (2020-2025)
  • Table 191. Competent Cells Contract Research Organizations (CROs) , by Region USD Billion (2020-2025)
  • Table 192. South America Competent Cells, by Country USD Billion (2020-2025)
  • Table 193. South America Competent Cells, by Type USD Billion (2020-2025)
  • Table 194. South America Competent Cells, by Application USD Billion (2020-2025)
  • Table 195. South America Competent Cells, by Phases USD Billion (2020-2025)
  • Table 196. South America Competent Cells, by Method USD Billion (2020-2025)
  • Table 197. South America Competent Cells, by End User USD Billion (2020-2025)
  • Table 198. Brazil Competent Cells, by Type USD Billion (2020-2025)
  • Table 199. Brazil Competent Cells, by Application USD Billion (2020-2025)
  • Table 200. Brazil Competent Cells, by Phases USD Billion (2020-2025)
  • Table 201. Brazil Competent Cells, by Method USD Billion (2020-2025)
  • Table 202. Brazil Competent Cells, by End User USD Billion (2020-2025)
  • Table 203. Argentina Competent Cells, by Type USD Billion (2020-2025)
  • Table 204. Argentina Competent Cells, by Application USD Billion (2020-2025)
  • Table 205. Argentina Competent Cells, by Phases USD Billion (2020-2025)
  • Table 206. Argentina Competent Cells, by Method USD Billion (2020-2025)
  • Table 207. Argentina Competent Cells, by End User USD Billion (2020-2025)
  • Table 208. Rest of South America Competent Cells, by Type USD Billion (2020-2025)
  • Table 209. Rest of South America Competent Cells, by Application USD Billion (2020-2025)
  • Table 210. Rest of South America Competent Cells, by Phases USD Billion (2020-2025)
  • Table 211. Rest of South America Competent Cells, by Method USD Billion (2020-2025)
  • Table 212. Rest of South America Competent Cells, by End User USD Billion (2020-2025)
  • Table 213. Asia Pacific Competent Cells, by Country USD Billion (2020-2025)
  • Table 214. Asia Pacific Competent Cells, by Type USD Billion (2020-2025)
  • Table 215. Asia Pacific Competent Cells, by Application USD Billion (2020-2025)
  • Table 216. Asia Pacific Competent Cells, by Phases USD Billion (2020-2025)
  • Table 217. Asia Pacific Competent Cells, by Method USD Billion (2020-2025)
  • Table 218. Asia Pacific Competent Cells, by End User USD Billion (2020-2025)
  • Table 219. China Competent Cells, by Type USD Billion (2020-2025)
  • Table 220. China Competent Cells, by Application USD Billion (2020-2025)
  • Table 221. China Competent Cells, by Phases USD Billion (2020-2025)
  • Table 222. China Competent Cells, by Method USD Billion (2020-2025)
  • Table 223. China Competent Cells, by End User USD Billion (2020-2025)
  • Table 224. Japan Competent Cells, by Type USD Billion (2020-2025)
  • Table 225. Japan Competent Cells, by Application USD Billion (2020-2025)
  • Table 226. Japan Competent Cells, by Phases USD Billion (2020-2025)
  • Table 227. Japan Competent Cells, by Method USD Billion (2020-2025)
  • Table 228. Japan Competent Cells, by End User USD Billion (2020-2025)
  • Table 229. India Competent Cells, by Type USD Billion (2020-2025)
  • Table 230. India Competent Cells, by Application USD Billion (2020-2025)
  • Table 231. India Competent Cells, by Phases USD Billion (2020-2025)
  • Table 232. India Competent Cells, by Method USD Billion (2020-2025)
  • Table 233. India Competent Cells, by End User USD Billion (2020-2025)
  • Table 234. South Korea Competent Cells, by Type USD Billion (2020-2025)
  • Table 235. South Korea Competent Cells, by Application USD Billion (2020-2025)
  • Table 236. South Korea Competent Cells, by Phases USD Billion (2020-2025)
  • Table 237. South Korea Competent Cells, by Method USD Billion (2020-2025)
  • Table 238. South Korea Competent Cells, by End User USD Billion (2020-2025)
  • Table 239. Taiwan Competent Cells, by Type USD Billion (2020-2025)
  • Table 240. Taiwan Competent Cells, by Application USD Billion (2020-2025)
  • Table 241. Taiwan Competent Cells, by Phases USD Billion (2020-2025)
  • Table 242. Taiwan Competent Cells, by Method USD Billion (2020-2025)
  • Table 243. Taiwan Competent Cells, by End User USD Billion (2020-2025)
  • Table 244. Australia Competent Cells, by Type USD Billion (2020-2025)
  • Table 245. Australia Competent Cells, by Application USD Billion (2020-2025)
  • Table 246. Australia Competent Cells, by Phases USD Billion (2020-2025)
  • Table 247. Australia Competent Cells, by Method USD Billion (2020-2025)
  • Table 248. Australia Competent Cells, by End User USD Billion (2020-2025)
  • Table 249. Rest of Asia-Pacific Competent Cells, by Type USD Billion (2020-2025)
  • Table 250. Rest of Asia-Pacific Competent Cells, by Application USD Billion (2020-2025)
  • Table 251. Rest of Asia-Pacific Competent Cells, by Phases USD Billion (2020-2025)
  • Table 252. Rest of Asia-Pacific Competent Cells, by Method USD Billion (2020-2025)
  • Table 253. Rest of Asia-Pacific Competent Cells, by End User USD Billion (2020-2025)
  • Table 254. Europe Competent Cells, by Country USD Billion (2020-2025)
  • Table 255. Europe Competent Cells, by Type USD Billion (2020-2025)
  • Table 256. Europe Competent Cells, by Application USD Billion (2020-2025)
  • Table 257. Europe Competent Cells, by Phases USD Billion (2020-2025)
  • Table 258. Europe Competent Cells, by Method USD Billion (2020-2025)
  • Table 259. Europe Competent Cells, by End User USD Billion (2020-2025)
  • Table 260. Germany Competent Cells, by Type USD Billion (2020-2025)
  • Table 261. Germany Competent Cells, by Application USD Billion (2020-2025)
  • Table 262. Germany Competent Cells, by Phases USD Billion (2020-2025)
  • Table 263. Germany Competent Cells, by Method USD Billion (2020-2025)
  • Table 264. Germany Competent Cells, by End User USD Billion (2020-2025)
  • Table 265. France Competent Cells, by Type USD Billion (2020-2025)
  • Table 266. France Competent Cells, by Application USD Billion (2020-2025)
  • Table 267. France Competent Cells, by Phases USD Billion (2020-2025)
  • Table 268. France Competent Cells, by Method USD Billion (2020-2025)
  • Table 269. France Competent Cells, by End User USD Billion (2020-2025)
  • Table 270. Italy Competent Cells, by Type USD Billion (2020-2025)
  • Table 271. Italy Competent Cells, by Application USD Billion (2020-2025)
  • Table 272. Italy Competent Cells, by Phases USD Billion (2020-2025)
  • Table 273. Italy Competent Cells, by Method USD Billion (2020-2025)
  • Table 274. Italy Competent Cells, by End User USD Billion (2020-2025)
  • Table 275. United Kingdom Competent Cells, by Type USD Billion (2020-2025)
  • Table 276. United Kingdom Competent Cells, by Application USD Billion (2020-2025)
  • Table 277. United Kingdom Competent Cells, by Phases USD Billion (2020-2025)
  • Table 278. United Kingdom Competent Cells, by Method USD Billion (2020-2025)
  • Table 279. United Kingdom Competent Cells, by End User USD Billion (2020-2025)
  • Table 280. Netherlands Competent Cells, by Type USD Billion (2020-2025)
  • Table 281. Netherlands Competent Cells, by Application USD Billion (2020-2025)
  • Table 282. Netherlands Competent Cells, by Phases USD Billion (2020-2025)
  • Table 283. Netherlands Competent Cells, by Method USD Billion (2020-2025)
  • Table 284. Netherlands Competent Cells, by End User USD Billion (2020-2025)
  • Table 285. Rest of Europe Competent Cells, by Type USD Billion (2020-2025)
  • Table 286. Rest of Europe Competent Cells, by Application USD Billion (2020-2025)
  • Table 287. Rest of Europe Competent Cells, by Phases USD Billion (2020-2025)
  • Table 288. Rest of Europe Competent Cells, by Method USD Billion (2020-2025)
  • Table 289. Rest of Europe Competent Cells, by End User USD Billion (2020-2025)
  • Table 290. MEA Competent Cells, by Country USD Billion (2020-2025)
  • Table 291. MEA Competent Cells, by Type USD Billion (2020-2025)
  • Table 292. MEA Competent Cells, by Application USD Billion (2020-2025)
  • Table 293. MEA Competent Cells, by Phases USD Billion (2020-2025)
  • Table 294. MEA Competent Cells, by Method USD Billion (2020-2025)
  • Table 295. MEA Competent Cells, by End User USD Billion (2020-2025)
  • Table 296. Middle East Competent Cells, by Type USD Billion (2020-2025)
  • Table 297. Middle East Competent Cells, by Application USD Billion (2020-2025)
  • Table 298. Middle East Competent Cells, by Phases USD Billion (2020-2025)
  • Table 299. Middle East Competent Cells, by Method USD Billion (2020-2025)
  • Table 300. Middle East Competent Cells, by End User USD Billion (2020-2025)
  • Table 301. Africa Competent Cells, by Type USD Billion (2020-2025)
  • Table 302. Africa Competent Cells, by Application USD Billion (2020-2025)
  • Table 303. Africa Competent Cells, by Phases USD Billion (2020-2025)
  • Table 304. Africa Competent Cells, by Method USD Billion (2020-2025)
  • Table 305. Africa Competent Cells, by End User USD Billion (2020-2025)
  • Table 306. North America Competent Cells, by Country USD Billion (2020-2025)
  • Table 307. North America Competent Cells, by Type USD Billion (2020-2025)
  • Table 308. North America Competent Cells, by Application USD Billion (2020-2025)
  • Table 309. North America Competent Cells, by Phases USD Billion (2020-2025)
  • Table 310. North America Competent Cells, by Method USD Billion (2020-2025)
  • Table 311. North America Competent Cells, by End User USD Billion (2020-2025)
  • Table 312. United States Competent Cells, by Type USD Billion (2020-2025)
  • Table 313. United States Competent Cells, by Application USD Billion (2020-2025)
  • Table 314. United States Competent Cells, by Phases USD Billion (2020-2025)
  • Table 315. United States Competent Cells, by Method USD Billion (2020-2025)
  • Table 316. United States Competent Cells, by End User USD Billion (2020-2025)
  • Table 317. Canada Competent Cells, by Type USD Billion (2020-2025)
  • Table 318. Canada Competent Cells, by Application USD Billion (2020-2025)
  • Table 319. Canada Competent Cells, by Phases USD Billion (2020-2025)
  • Table 320. Canada Competent Cells, by Method USD Billion (2020-2025)
  • Table 321. Canada Competent Cells, by End User USD Billion (2020-2025)
  • Table 322. Mexico Competent Cells, by Type USD Billion (2020-2025)
  • Table 323. Mexico Competent Cells, by Application USD Billion (2020-2025)
  • Table 324. Mexico Competent Cells, by Phases USD Billion (2020-2025)
  • Table 325. Mexico Competent Cells, by Method USD Billion (2020-2025)
  • Table 326. Mexico Competent Cells, by End User USD Billion (2020-2025)
  • Table 327. Research Programs/Design for This Report
  • Table 328. Key Data Information from Secondary Sources
  • Table 329. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Competent Cells: by Type USD Billion (2014-2019)
  • Figure 5. Global Competent Cells: by Application USD Billion (2014-2019)
  • Figure 6. Global Competent Cells: by Phases USD Billion (2014-2019)
  • Figure 7. Global Competent Cells: by Method USD Billion (2014-2019)
  • Figure 8. Global Competent Cells: by End User USD Billion (2014-2019)
  • Figure 9. South America Competent Cells Share (%), by Country
  • Figure 10. Asia Pacific Competent Cells Share (%), by Country
  • Figure 11. Europe Competent Cells Share (%), by Country
  • Figure 12. MEA Competent Cells Share (%), by Country
  • Figure 13. North America Competent Cells Share (%), by Country
  • Figure 14. Global Competent Cells share by Players 2019 (%)
  • Figure 15. Global Competent Cells share by Players (Top 3) 2019(%)
  • Figure 16. Global Competent Cells share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck KGaA (Germany) Revenue: by Geography 2019
  • Figure 20. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. Promega Corporation (United States) Revenue: by Geography 2019
  • Figure 22. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2019
  • Figure 24. New England Biolabs (United States) Revenue, Net Income and Gross profit
  • Figure 25. New England Biolabs (United States) Revenue: by Geography 2019
  • Figure 26. Takara Bio (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Takara Bio (Japan) Revenue: by Geography 2019
  • Figure 28. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 29. Agilent Technologies (United States) Revenue: by Geography 2019
  • Figure 30. Lucigen (United States) Revenue, Net Income and Gross profit
  • Figure 31. Lucigen (United States) Revenue: by Geography 2019
  • Figure 32. QIAGEN N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 33. QIAGEN N.V. (Germany) Revenue: by Geography 2019
  • Figure 34. OriGene Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 35. OriGene Technologies (United States) Revenue: by Geography 2019
  • Figure 36. Bioline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Bioline (United Kingdom) Revenue: by Geography 2019
  • Figure 38. Zymo Research (United States) Revenue, Net Income and Gross profit
  • Figure 39. Zymo Research (United States) Revenue: by Geography 2019
  • Figure 40. Beijing TransGen Biotech Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 41. Beijing TransGen Biotech Co., Ltd. (China) Revenue: by Geography 2019
  • Figure 42. Source BioScience (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 43. Source BioScience (United Kingdom) Revenue: by Geography 2019
  • Figure 44. IBA GmBH (Germany) Revenue, Net Income and Gross profit
  • Figure 45. IBA GmBH (Germany) Revenue: by Geography 2019
  • Figure 46. Genewiz (United States) Revenue, Net Income and Gross profit
  • Figure 47. Genewiz (United States) Revenue: by Geography 2019
  • Figure 48. BioDynamics Laboratory, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 49. BioDynamics Laboratory, Inc. (Japan) Revenue: by Geography 2019
  • Figure 50. Global Competent Cells: by Type USD Billion (2020-2025)
  • Figure 51. Global Competent Cells: by Application USD Billion (2020-2025)
  • Figure 52. Global Competent Cells: by Phases USD Billion (2020-2025)
  • Figure 53. Global Competent Cells: by Method USD Billion (2020-2025)
  • Figure 54. Global Competent Cells: by End User USD Billion (2020-2025)
  • Figure 55. South America Competent Cells Share (%), by Country
  • Figure 56. Asia Pacific Competent Cells Share (%), by Country
  • Figure 57. Europe Competent Cells Share (%), by Country
  • Figure 58. MEA Competent Cells Share (%), by Country
  • Figure 59. North America Competent Cells Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • Promega Corporation (United States)
  • Thermo Fisher Scientific, Inc. (United States)
  • New England Biolabs (United States)
  • Takara Bio (Japan)
  • Agilent Technologies (United States)
  • Lucigen (United States)
  • QIAGEN N.V. (Germany)
  • OriGene Technologies (United States)
  • Bioline (United Kingdom)
  • Zymo Research (United States)
  • Beijing TransGen Biotech Co., Ltd. (China)
  • Source BioScience (United Kingdom)
  • IBA GmBH (Germany)
  • Genewiz (United States)
  • BioDynamics Laboratory, Inc. (Japan)
Additional players considered in the study are as follows:
GCC Biotech (India) , SMOBIO Technology (Taiwan) , GeneScript Corporation (United States) , Bio-Rad Laboratories (United States) , Life Technologies (India) Pvt. Ltd. (India) , Cell Applications, Inc. (United States) , Delphi Genetics (Belgium) , Scarab Genomics, LLC (U.S.) , Yeastern Biotech Co., Ltd. (Taiwan)
Select User Access Type

Key Highlights of Report


Mar 2020 215 Pages 71 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Competent Cells research Quantitative research analysis
Global Competent Cells research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Competent Cells research Report?

Have a Query? Click Here

Other Related Reports

Oral Vaccines Comprehensive Study by Type (Live (attenuated), Inactive, Recombinant, Other), Application (Polio, Rabies, Tuberculosis, Influenza, Respiratory infections, HIV, Cholera, Rotavirus, Othe...
$ 3450
Biobanking Comprehensive Study by Type (Equipment, Consumables, Services, Software), Application (Regenerative Medicine, Life Science Research, Clinical Research), Ownership (National/Regional Agenci...
$ 3750
Clinical Microbiology Comprehensive Study by Application (Pharmaceutical, Food Testing, Energy, Chemical and Material Manufacturing, Environment), End Users (Hospital, Diagnolab, Academia), Disease (...
$ 3750
Animal Hormones Comprehensive Study by Application (Growth Promoters, Performance Enhancers, Others), End-Use (Poultry, Porcine, Livestock, Equine, Aquaculture, Other) Players and Region - Global Mar...
$ 3500
Exosomes Comprehensive Study by Application (Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Others), Downstream Analysis (Cell Surface Marker Analysis using Flow Cy...
$ 3750
Cell Banking Outsourcing Comprehensive Study by Type (Master Cell Banking, Working Cell Banking, Viral Cell Banking), Phase (Preparation, Testing, Characterization), Bank Storage (Master Cell Bank St...
$ 3800